Aldeyra Therapeutics Company Description

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.

Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa.

The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication.

In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases.

The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.